Authors: BRUNVEZINET F BOUCHER C LOVEDAY C DESCAMPS D FAUVEAU V IZOPET J JEFFRIES D KAYE S KRZYANOWSKI C NUNN A SCHUURMAN R SEIGNEURIN JM TAMALET C TEDDER R WEBER J WEVERLING GJ ABER V ABOULKER JP BABIKER AG BRAGMAN K BRECKENRIDGE AM CARBON C CHARREAU I CHENE G COLLIS P COOPER D DARBYSHIRE JH DORMONT J FIDDIAN P FLEPP M GAZZARD B GOEBEL FD HOOKER M LANGE J LUTHY R PETO TEA REISS P SELIGMANN M STONE AB THOMIS J VELLA S WALCKENAER G WARRELL D WELLER IVD WILBER R YENI P YEO J WITHNALL R BABIKER A BLOCH J POUCHER C DARBYSHIRE J GOUDSMIT J HURAUX JM VANDERNOORDAA J WEISS R WEVERLING G

Citation: F. Brunvezinet et al., HIV-1 VIRAL LOAD, PHENOTYPE, AND RESISTANCE IN A SUBSET OF DRUG-NAIVEPARTICIPANTS FROM THE DELTA-TRIAL, Lancet, 350(9083), 1997, pp. 983-990

Authors: ABER V ABOULKER JP BABIKER AG BRAGMAN K BRECKENRIDGE AM CARBON C CHARREAU I CHENE G COLLIS P COOPER D DARBYSHIRE JH DORMONT J FIDDIAN P FLEPP M GAZZARD B GOEBEL FD HOOKER M LANGE J LUTHY R PETO TEA REISS P SELIGMANN M STONE AB THOMIS J VELLA S WALCKENAER G WARRELL D WELLER IVD WILBER R YENI P YEO J WITHNALL R

Citation: V. Aber et al., DELTA - A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL COMPARING COMBINATIONS OF ZIDOVUDINE PLUS DIDANOSINE OR ZALCITABINE WITH ZIDOVUDINE ALONE IN HIV-INFECTED INDIVIDUALS, Lancet, 348(9023), 1996, pp. 283-291